Vir, Phase 2

Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?
Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market cap, see if VIR stock is a Buy now.
Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58%
Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir Biotechnology ( VIR, Financials) saw a notable 58% increase in its stock price, thereby emphasizing developments in its oncology pipeline.
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies.
Vir Biotech upgraded at Morgan Stanley on cancer drug data
Vir Biotechnology (VIR) stock was upgraded by Morgan Stanley after the company posted trial data for two antitumor agents developed with Sanofi (SNY). Read more here.
Vir Biotechnology Reports Promising Trial Results for Cancer Therapies
Vir Biotechnology ( (VIR) ) has issued an update. Vir Biotechnology announced promising Phase 1 trial results for its dual-masked T-cell engagers, VIR-5818 and VIR-5500, targeting HER2-expressing solid tumors and PSMA in metastatic castration-resistant prostate cancer respectively.
Vir Biotech Shares Rise on Positive Data for Cancer Treatments
Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. The clinical-stage biopharmaceutical company said VIR-5818 targets HER2-expressing solid tumors,
Vir Biotechnology presents safety, efficacy data in VIR-5818 and VIR-5500 trials
Vir Biotechnology (VIR) is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of
Hosted on MSN9h
Morgan Stanley Upgrades Vir Biotechnology (VIR)
Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal ...
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20
Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an "overweight" rating, shifting from ...
Vir Biotechnology’s Promising TCE Oncology Assets Earn Buy Rating from Joseph Stringer
Vir Biotechnology (VIR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer ...
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer
Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first positive data since it executed a major pivot last summer. A hot stock during the ...
bovnews1d
Vir Biotechnology Inc (VIR) Stock: Surpassing Expectations in the Market?
JP Morgan has recently reduced Vir Biotechnology Inc (VIR) stock to Neutral rating, as announced on January 29, 2024, according to Finviz. Earlier, on September 8, 2023, BofA Securities had reduced ...
Vir Biotechnology’s Early Promise in Clinical Trials Warrants Hold Rating Amid Uncertainties
Morgan Stanley analyst Michael Ulz maintained a Hold rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...
Vir Biotechnology price target lowered to $14 from $15 at BofA
BofA lowered the firm’s price target on Vir Biotechnology (VIR) to $14 from $15 and keeps a Neutral rating on the shares. While political and rate uncertainty continues to be an overhang, the firm ...
bovnews1d
Vir Biotechnology (VIR) Makes Big Waves: Why Today’s Stock Surge Matters
Vir Biotechnology, Inc. (Nasdaq: VIR) is experiencing a massive surge in the stock market, climbing an impressive +74.08% or $5.85 to $13.74 in Wednesday’s trading session at 12:22 PM EST. This sharp ...